Intervention Review

You have free access to this content

Tiagabine add-on for drug-resistant partial epilepsy

  1. Jennifer Pulman1,*,
  2. Jane L Hutton2,
  3. Anthony G Marson1

Editorial Group: Cochrane Epilepsy Group

Published Online: 5 FEB 2014

Assessed as up-to-date: 11 NOV 2013

DOI: 10.1002/14651858.CD001908.pub3


How to Cite

Pulman J, Hutton JL, Marson AG. Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD001908. DOI: 10.1002/14651858.CD001908.pub3.

Author Information

  1. 1

    Institute of Translational Medicine, University of Liverpool, Department of Molecular and Clinical Pharmacology, Liverpool, Merseyside, UK

  2. 2

    University of Warwick, Department of Statistics, Coventry, UK

*Jennifer Pulman, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Clinical Sciences Centre for Research and Education, Lower Lane, Fazakerley, Liverpool, Merseyside, L9 7LJ, UK. jennifer.pulman@liv.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 5 FEB 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Crawford 2001 {published and unpublished data}
Fritz 2005 {published data only}
  • Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy & Behavior 2005;6(3):373-81.
Kalviainen 1998 {published and unpublished data}
  • Kalviainen R, Aikia M, Mervaala E, Saukkonen AM, Pitkanen A, Riekkinen PJ Sr. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Research 1996;25(3):291-7.
  • Kalviainen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Epilepsy Research 1998;30:31-40.
Richens 1995 {published and unpublished data}
  • Richens A, Chadwick DW, Duncan JS, Dam M, Gram L, Mikkelsen M, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Research 1995;21(1):37-42. [MEDLINE: 95369226; : CN-00015195 - CCTR]
  • Sveinbjornsdottir S, Sander JW, Patsalos PN, Upton D, Thompson PJ, Duncan JS. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994;3(1):29-35.
Sachdeo 1997 {published and unpublished data}
Uthman 1998 {published and unpublished data}

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Arroyo 2005 {published data only}
Bauer 1995 {published data only}
  • Bauer J, Stawowy B, Lenders T, Bettig U, Elger CE. Efficacy and tolerability of tiagabine: results of an add-on study in patients with refractory partial seizures. Journal of Epilepsy 1995;8(1):83-6.
Gustavson 1997 {published data only}
  • Gustavson LE, Boellner SW, Granneman GR, Qian JX, Guenther HJ, El-Shourbagy T, et al. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997;48(4):1032-7.
Uldall 1995 {published data only}
  • Uldall P, Bulteau C, Pedersen SA, Dulac O, Meinild H, Lassen LC. Single-blind study of safety, tolerability and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy. Epilepsia 1995;36 Suppl(3):S147-S148.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Baker 2000
Cochrane 1998
Cockerell 1995
Commission 1989
Dodrill 1997
Hauser 1993
Higgins 2010
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, Ltd, 2010.
Kalviainen 1996
  • Kalviainen R, Aikia M, Mervaala E, Saukkonen AM, Pitkanen A, Riekkinen PJ Sr. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Research 1996;25(3):291-7.
Kirkham 2010
  • Kirkham J, Dwan K, Altman D, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. British Medical Journal 2010;340:365.
Lefebvre 2009
  • Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. www.cochrane-handbook.org.
Marson 1996
Marson 1997
McCullagh 1989
  • McCullagh P, Nelder JA. Generalized Linear Models. 2nd Edition. London: Chapman and Hall, 1989.
Ostergaard 1995
  • Ostergaard LH, Gram L, Dam M. Tiagabine. In: Levy RH, Mattson RH, Medlrum BS editor(s). Mechanisms of Action in Antiepileptic Drugs. 4th Edition. New York: Raven Press, 1995.
Sander 1996
Sveinbjornsdottir 1994
  • Sveinbjornsdottir S, Sander JW, Patsalos PN, Upton D, Thompson PJ, Duncan JS. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994;3(1):29-35.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Pulman 2012